15 16 The innate immune response induced by type I interferons (IFNs) play a critical role in the 17 establishment of HIV infection. IFNs are induced early in HIV infection and trigger an antiviral 18 defense program by signaling through the IFNa/b receptor (IFNAR), which consists of two 19
shows the strongest substantial depletion of CD4 + T cells, occurring mostly in CD4 + CCR5 + T 46 cells [4, 5] in comparison to peripheral mononuclear blood cells (PBMCs) which are 47 commonly used for studying HIV immune responses. An earlier study conducted with simian 48 immunodeficiency virus (SIV) proved the CD4 + T cell depletion not only to be more severe, 49 but also to occur much faster in the GALT [6] and showed a delayed restoration of CD4 + T 50 cell numbers following early combined antiretroviral therapy (cART) initiation in comparison 51
to PBMCs [7] . As Lamina propria mononuclear cells (LPMCs) can be infected efficiently by 52 CCR5-tropic HIV-1 strains without the need for exogenous stimulation, the Lamina propria 53 aggregate culture (LPAC) can be used as an efficient ex vivo model to study HIV infection 54 close to the physiological background [8] . 55
Since adaptive immunity has yet to be mounted in the early stages of infection, innate 56 immune responses are of great importance as the first line of defense. Early host immune 57 responses in the GALT are mediated by type I interferons (IFNs), which are mainly secreted 58 by plasmacytoid dendritic cells (pDC) [9] . Type I IFNs are a pleiotropic cytokine family 59 consisting of IFNα, IFNβ, IFNε, IFNκ and IFNω. The human chromosome 9 contains 13 60 genes encoding for 12 individual IFNα subtypes [10] , highly conserved proteins with an 61 amino acid sequence homology of 75-99 % [11] . All type I IFNs bind to the common IFNα/β 62 receptor (IFNAR), which is widely expressed on most cell types [12] . The receptor consists of 63 two subunits, IFNAR1 and IFNAR2, which associate with Janus kinases (Jak) Tyk2 (IFNAR1) 64 and Jak1 (IFNAR2). Upon initial ligand binding by IFNAR2, IFNAR1 is recruited and 65 subsequent to formation of the ternary complex out of IFNAR1, IFNAR2 and IFNα or IFNβ, 66 Tyk2 and JAK1 become activated. Type I IFN signal transduction commonly takes place via 67 the classical Jak-STAT pathway leading to the transcription of numerous IFN-stimulated 68 genes (ISGs), among them several genes that encode for proteins with direct antiviral 69 activity, e.g., apolipoprotein B mRNA editing enzyme, catalytic polypeptide like (APOBEC), 70 SAM domain and HD domain containing protein 1 (SamHD1) and interferon induced GTP 71 binding protein MX2 (MX2). Additionally, IFNα subtypes indirectly exert immunomodulatory 72 functions and anti-proliferative effects on cells of the innate and adaptive immune system 73 [13] . The IFNAR2 subunit is of special interest, as it is responsible for initial ligand binding 74 and three different isoforms are described. IFNAR2c contains long intracellular domains with 75 associated kinases and is responsible for signal transduction. IFNAR2b is likewise a 76 membrane bound isoform lacking the intracellular domains, which is thought to be a negative 77 regulator for type I IFN signaling [14] . Meanwhile, IFNAR2a is a soluble isoform, produced by 78 either alternative splicing or by proteolytic cleavage at the cell surface and, in the murine 79 organism, independently regulated from trans-membranous IFNAR2 [15] . It is known to be 80 increased in multiple sclerosis [16] , adeno carcinoma and lung cancer [17, 18] and was found 81 to be elevated and negatively correlated with successful IFN therapy in Hepatitis C patients 82 [19] . 83
Compared to healthy individuals, IFNα expression is increased and the specific expression 84 pattern of IFNα subtypes is changed in HIV + patients. [20] [21] [22] . Even though the exact role of 85
IFNs in HIV infection is still under debate, beneficial implications of IFNα as suppressed viral 86 load, increased NK cell function and enhanced suppressive capacity of CD8 + T cells as well 87 as an increase in the expression of ISGs containing HIV restriction factors and thus hindering 88 viral transmission and replication could be observed [23] [24] [25] . On the other hand, rescued 89 CD4 + T cell depletion and restored cell function following blockade of IFNAR was reported 90 [23, 26] , as well as systemic immune activation and limited antigen-specific T cell responses 91
[24], thus indicating a potential detrimental influence of IFN on the course of HIV infection. 92
Due to their high antiviral potential, several studies testing IFNα as a treatment option for HIV 93 were conducted, but patients showed no or only mild benefits from the treatment [27] [28] [29] . 94
This, along with the development of highly effective antiretroviral therapies, led to decreased 95 interest in IFNα as a potential therapeutic strategy against HIV [30] . Furthermore, several 96 studies showed that the clinically approved IFNα2 subtype possesses only weak antiviral 97 activity against HIV [9, 31] . Thus the question remains, wether an IFNα subtype with higher 98 antiviral capacities against HIV, such as IFNα14, might be of more use against HIV, for 99 example as a potential addition to cART. Initial studies with humanized mice using IFNα14 as 100 an antiviral agent showed promising results. In contrast to IFNα2 treatment, IFNα14 was able 101 to reduce viremia and proviral loads in post-exposure prophylaxis and treatment of acute 102 infection and reduced hyperimmune activation [31] . Furthermore, gene therapy with plasmids 103 encoding for IFNα14, but not for IFNα2, was shown to provide long-term suppression of HIV 104 replication [32] . 105
Even though the individual IFNα subtypes exert different biological responses, they all bind to 106 the same receptor. One factor possibly influencing the diverse biological outcome is the 107 different affinity of IFNα subtypes to both receptor subunits IFNAR1 and IFNAR2 [33] . For 108 IFNAR2, a correlation between antiviral activity and receptor affinity was observed [9] , while 109 anti-proliferative effects seem to be more associated with the affinity to IFNAR1 and the 110 stability of the ternary complex, respectively [33, 34] . 111
Various factors regulate the biological response to IFNα stimulation. The affinity of the 112 individual IFNα subtype to both receptor subunits und their cell surface density is pivotal. 113
Combined with the dose of IFNα the cell is receiving, the overall avidity of an individual IFNα 114 subtype is a major determinant for the biological outcome [35, 36] . Cell-type specific effects 115 as well as microenvironment based factors, e.g. downregulation of IFNAR1 in Influenza A 116 infections [37] or in colorectal cancer [38] also modulate the IFNα response. Additionally, the 117 precise timing of exposure to IFNα in reference to proceeding or subsequent priming of the 118 target cells as well as the duration of ligand binding shape the biological outcome [35] . 119
Ligand-binding induced receptor downregulation is described for both receptor subunits on 120 different cell lines following stimulation with IFNα2 and IFNβ [39] . According to its higher 121 affinity to the receptor, IFNβ stimulation decreased the receptor surface expression to much 122 stronger extents [39] . Homburg an der Höhe, Germany). Cells were incubated at 1x10 6 cells/ml at 37 °C and 5% 155 CO 2 for the indicated time period. LPMC collection was approved by the Ethics Committee 156 Expression of IFNAR2 isoforms 256 The IFNAR2 receptor subunit is expressed in three different isoforms: IFNAR2a, IFNAR2b 257 and IFNAR2c. IFNAR2c and IFNAR2b are membrane-bound isoforms, IFNAR2c being 258 responsible for signal transduction while IFNAR2b, which lacks the necessary intracellular 259 domains, is thought to be a negative regulator for type I IFN signaling [14] . IFNAR2a is a 260 soluble isoform, which can be produced through alternative splicing or proteolytic cleavage 261 from the cell surface. Since we could not observe any difference in IFNAR2b/c surface 262 expression following HIV-infection (Fig. 1) , we next analyzed the expression of soluble 263 IFNAR2 (sIFNAR2a) in the supernatant of mock-treated and HIV-infected LPMCs at days 1, 264 3, 4, 5, 6 and 7 post infection via ELISA (Fig. 2a, data shown for day 4) . Similar to the 265 surface expression of IFNAR2 (Fig. 1) , we did not observe any significant differences in the 266 sIFNAR2a expression between mock-treated (mean 0.3 ng/ml) and HIV-infected LPMCs 267 (mean 0 ng/ml) ( Fig. 2a ). To examine possible effects of HIV-1 infection in vivo, we 268 compared the sIFNAR2 expression in plasma samples of healthy donors (mean 0.41 ng/ml) 269 with plasma samples of HIV-1 + cART-naïve (mean 0.40 ng/ml) and cART-experienced 270 patients (mean 0.21 ng/ml) ( Fig. 2b) . According to the in vitro HIV-infected LPMC results, 271 sIFNAR2a levels did not significantly differ between the groups. Furthermore, we did not find 272 any correlation between viral loads and sIFNAR2a expression in cART-naïve patients (data 273 not shown). Additionally, no association between the cART regimen and sIFNAR2a 274 expression was observed in cART-experienced HIV + -patients (data not shown). their antiviral capacity against HIV [9, 31] , we sought to compare subtypes with very high 290 (IFNα8 & IFNα14) to those with very low (IFNα1 & IFNα2) antiviral activities, with respect to 291 their potential to influence receptor expression. Furthermore, we chose IFNα subtypes 292 representing subtypes high with (α14, α2), middle (α8) and low (α1) affinity to IFNAR2. 293
LPMCs from four different healthy donors were stimulated with the half maximally effective 294 concentration (EC 50 ; Fig. 3) of IFNα1, IFNα2, IFNα8 and IFNα14 for 15 min, 30 min, 2 h and 295 24 h. Subsequently, surface receptor expression was determined via flow cytometry. We did 296 not see significant differences in the surface expression of IFNAR2 on CD4 + and CD8 + T 297 cells, B cells and NK cells after stimulation with the different IFNα subtypes. Furthermore, 298 stimulation did not lead to changes in IFNAR2 expression compared to the unstimulated 299 control. Slight elevations of IFNAR2 expression up to approximately 130% compared to the 300 unstimulated control were observed 24 h following stimulation for all tested cell populations. 301
Interestingly, one of the four tested LPMC donors exhibited an increase of IFNAR2 302 expression of 270% on CD8 + T cells when stimulated (Fig. 4) . In addition to the percentages 303 of IFNAR2 expressing cells, no differences were detected at the single cell level when 304 analyzing the MFI (data not shown). other subtypes, such as IFNα14, are highly antiviral against HIV [9, 31] . In this study, we 329 aimed to determine whether the different responses are based on differential expression of 330 IFNAR2 on various immune cell populations and if receptor expression levels might be 331 altered upon infection with HIV. Indeed we could find strong differences in the percentages of 332 IFNAR2 expressing cells, which were almost three times as high on B cells compared to 333 CD4 + and CD8 + T cells (Fig. 1) . These findings are in agreement with other studies, which 334 also showed higher expression of IFNAR2 on B and NK compared to T cells [43, 44] . 335
Whereas Killian et al. [45] observed increased IFNAR2 expression on CXCR4 + CD4 + T cells 336 in whole blood of HIV + patients compared to healthy donors, we did not see any differences 337 in IFNAR2 surface expression on the analyzed immune cell subsets following HIV infection of 338 itself [45] . Other studies in mouse models reported a downregulation of IFNAR1 and IFNAR2 352 during influenza A infections, caused by viral proteins [37, 46] . Influenza A was also shown to 353 downregulate IFNAR1 and IFNAR2 in human monocyte-derived macrophages, however ex 354 vivo infection of human lung tissue with Influenza A only reduced the expression of IFNAR1, 355 but not IFNAR2 [46] . Among the two subunits, IFNAR1 expression seems to be more 356 stringently regulated [12] and stable expression on the cell surface requires the binding of Tyk2 to its intracellular domains [47, 48] . While IFNAR1 is directed towards lysosomal 358 degradation following downregulation from the cell surface, the fate of IFNAR2 seems to 359 depend on the ligand: Following IFNα stimulation, IFNAR2 is rapidly recycled back to the cell 360 surface, though it is targeted for degradation upon binding of IFNβ [49] . By comparing 361 IFNAR1 -/and IFNAR2 -/mouse models, distinct roles for each subunit in regulating the 362 immune response against Influenza A could be discerned. Whereas the full receptor was 363 needed for complete protection against Influenza A infection, higher morbidity, mortality and 364 increased viral burden in IFNAR2 -/mice indicate a more extensive role of IFNAR2 in antiviral 365 immunity. Furthermore, stimulation with IFNβ was able to induce protection from lethal 366 Influenza A infection in IFNAR1 -/mice, but not in IFNAR2 -/mice. In comparison, IFNAR2 -/ -367 mice were better able to control bacterial superinfections subsequent to Influenza A infection 368 [50] . FNβ is reported to be able to bind IFNAR1 independently from IFNAR2 [51] , which 369 further strengthens the possibility of distinct roles for reach receptor subunit. Also in HIV, 370 different functions and regulation for IFNAR1 and IFNAR2 are possible. As the majority of 371 data concerning IFNAR1 and IFNAR2 expression and regulation were generated using 372 mouse models or cell lines, one has to be careful with translating these findings to humans. 373
Though IFNα/β signaling plays an absolutely crucial role in mounting immune responses and 374 protection against viral infection in mice, a recent translational report from Duncan and 375 colleagues about a patient deficient in IFNAR2 challenged this perspective, stating that as 376 long as infections in humans are local and not systemic, lack of IFNα/β signaling has no 377 effect on the development of T cells and does not increase the susceptibility towards 378 respiratory infections [52] . 379
Our findings concerning the expression of the soluble isoform of IFNAR2, sIFNAR2a, are in 380 accordance with the results for IFNAR2b/c surface expression. We detected trace amounts 381 of sIFNAR2a in the supernatant of HIV-infected LPMCs ( Fig. 2A ) and we did not see any 382 difference in sIFNAR2a concentrations in the plasma of healthy donors and HIV + cART-naïve 383 and cART-experienced patients (Fig. 2B) . 384
Both agonistic and antagonistic properties of sIFNAR2a where shown in mice, specifically 385 their ability to influence the efficacy of therapeutic IFNα treatment [15, 53] . In mouse cell lines 386 and primary cells overexpressing sIFNAR2a, the antiproliferative and antiviral effects of IFNα 387 and IFNβ stimulation were inhibited. Recombinant sIFNAR2a was able to bind IFNα and 388
IFNβ and complex with IFNAR1 on the surface of IFNAR2 -/thymocytes, leading to an 389 antiproliferative response [15] . A later study by the same group proofed transgenic mice with 390 elevated sIFNAR2 expression to be more susceptible to LPS-mediated septic shock, in 391 which IFNβ plays a major role. Spleen cells of those transgenic mice overexpressing 392 sIFNAR2a showed a faster, higher and more sustainable activation of STAT1 and STAT3, 393 hence highlighting the agonistic abilities of sIFNAR2a [53] . Organ-dependent ratios of the 394 mRNA for sIFNAR2a versus the mRNA for transmembranous IFNAR2 indicate an 395 independent regulation from transmembranous IFNAR2 and a possibly organ specific 396 biological function [15] . In humans, sIFNAR2a is reported to be elevated in systemic lupus 397 during hepatitis C infection, in which sIFNAR2a expression was found to be predictive for the 403 response to IFNα2 therapy [19] . One study reported a negative correlation between IFNAR2a 404 expression and B cell exhaustion as well as impaired antibody production in the blood of 405 HIV + ART-treated, but not HIV + ART naïve patients [56] , which implicates ART rather than 406 HIV itself as the primary effector and thus supports the data mentioned before [45] . Since we 407 did not perform functional analysis of B cells in our samples, we cannot exclude the 408 possibility of an association between sIFNAR2a levels and impaired B cell function. Given 409 that we did not observe any difference between cART-naïve and cART-experienced patients, 410
it is rather unlikely that HIV infection has any influence on the expression of the different 411 IFNAR2 isoforms on LPMCs. 412
One factor influencing the diverse biological response of IFNα subtypes are their different 413 affinities to IFNAR1 and IFNAR2, supported by the fact that affinity to IFNAR2 was reported 414 to positively correlate with their antiviral activity against HIV [9] . To this end, we analyzed the 415 effect of stimulating LPMCs with four IFNα subtypes, representing subtypes with high 416 (IFNα14), middle (IFNα2 & IFNα8) and low (IFNα1) binding affinity to IFNAR2. Though IFNα8 417 and especially IFNα14 are highly antiviral against HIV, IFNα1 and IFNα2 exhibit only weak 418 antiviral effects against HIV [9, 31, 33 ]. With all four tested subtypes, we did not see any 419 differences in IFNAR2 expression on CD4 + T cells, CD8 + T cells, B cells or NK cells at 15 420 min, 30 min, 2 h and 24 h post stimulation (Fig. 4) . Important factors for shaping the 421 biological response of IFNα are the exposure time of the ligand, the receptor density 422 expressed on the cell surface, the kinetics of its downregulation as well as the dose of the 423 ligand [35] . Following IFN-stimulation with much higher concentrations than the reported 424 EC 50 , we observed a downregulation of IFNAR2 on lymphocytes (unpublished data), 425 however these concentrations exceed physiologically tolerable levels of IFNα, and thus are 426 not applicable for therapeutic treatments. With all IFNα subtypes possessing different affinities to both receptor subunits, it is likely that 432 they also differ in their influence on ligand induced downregulation of the receptor. Several 433 studies have shown downregulation of both IFNAR1 and IFNAR2 after ligand stimulation on 434 cell lines [39] and on human PBMCs [44] , however, only IFNα2 was tested in these studies. 435
In contrast to our findings, Tochizawa et al. [44] observed decreased IFNAR2 expression on 436
PBMCs following 2 h stimulation with 100 U/ml and 1000 U/ml IFNα2, the latter being equal 437 to the EC 50 for IFNα2 used in our experiments. As discussed above, it is possible that 438 LPMCs react differently than PBMCs to IFNα stimulation and further elucidation of which cell 439 types exactly exhibit the observed IFNAR2 downregulation is needed. Out of the four cell 440 lines tested by Marijanovic et al. [39] , IFNAR2 downregulation was only detected on 441
Hek293T cells and on HeLa cells, but not on Daudi or Jurkat cells. Among those four, Daudi 442 and Jurkat cells are the only ones originating from immune cells, with Daudi cells being 443
Burkitt Lymphoma cells and Jurkat cells originate from human T cells. Thus, the expression 444 profile of IFNAR1 and IFNAR2 on Daudi and Jurkat cells is more likely to resemble the 445 expression profile of human ex vivo samples than the expression profile of HeLa and 446
Hek293T cells. Additionally, the downregulation measured on HeLa and Hek293T cells was 447 more pronounced for IFNAR1 than it was for IFNAR2. As mentioned previously, the 448 expression of IFNAR1 on the cell surface is tightly regulated [47] . Even though we could not 449 detect an effect of IFNα stimulation on the expression of IFNAR2, it is likely that IFNAR1 450 expression is more sensitive to IFNα subtype induced downregulation and its expression has 451 greater influence in shaping the IFNα subtype dependent biological response. 452
In conclusion, neither HIV infection nor IFNα stimulation seem to influence the expression of 453 IFNAR2, which therefore likely does not to affect the IFN responsiveness of cells in the gut 454 during HIV infection. 455
